A team of researchers at Robert Gordon University has secured a six figure sum from Sparks, a leading children’s medical research charity, to develop a revolutionary treatment for a rare genetic disorder.
31 August, 2011
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack [myocardial infarction (MI)].
26 August, 2011
A team led by Professor Stephen Jackson together with Cancer Research Technology (Cancer Research UK’s commercial arm) and the University of Cambridge has announced the launch of MISSION Therapeutics Ltd, with Series A funding from a top venture capital syndicate.
25 August, 2011
KalVista Pharmaceuticals, a new ophthalmology company with a focus on diabetic macular edema (DME), has raised £8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
24 August, 2011
Cancer Research UK-funded scientists have discovered that a protein called JAK triggers contractions in tumours which enable cancer cells to squeeze though tiny spaces and spread.
16 August, 2011
High levels of fat shut down a key enzyme that promotes glucose sensing in pancreatic beta cells, revealing a pathway implicated in the Type 2 diabetes epidemic.
15 August, 2011
The European Commission (EC) approved Boehringer Ingelheim’s breakthrough oral anticoagulant, Pradaxa® (dabigatran etexilate) for the prevention of stroke in patients with atrial fibrillation (AF) at risk of stroke. This EU label extension means that, for the first time in over 50 years, millions of AF patients across Europe will have access to a new treatment for the prevention of AF-related strokes, which is effective and convenient, and has demonstrated a good safety profile.
05 August, 2011